These findings collectively suggest that CHRDL2 overexpression could affect response to CRC therapy by enhancing DNA repair and the stem‐cell potential of cancer cells, and its role as a biomarker should be further explored. This evidence concerns the gene CHRDL2 and colorectal carcinoma.